on May 25, before the FDA announced the latest Ozempic and Wegovy shortage at the end of May, Novo Nordisk said that all doses of Ozempic were available to pharmacies for appropriate patients with type 2 diabetes, and that pharmacies may experience normal delays given the time required to order the product from their local distribution center, and geographical variabilities. While reporting this story, Novo Nordisk said, with respect to Wegovy, that prescribing trends continue to increase at a substantial rate and indicate that demand for Wegovy in the U.S
[4] Other Applicants Under Review Several additional generic manufacturers have submissions under Health Canada review, including Sandoz, Teva Canada, Taro Pharmaceuticals, Aspen Pharmacare, and Vimy Pharma (an Edmonton-based company co-founded by former Novo Nordisk Canada executives)
Next Step Start Your Weight Loss Journey Schedule a consultation to review options, pricing, and whether this treatment path is right for you
And having that data can help dictate if you need to modify your plan and ensure you are losing mostly body fat, not muscle. She says the Renpho Smart Scale is a great choice because its super-affordable, FSA/HSA eligible, and most importantly, easy to use
However, results in human trials are less favourable with no difference in weight between obese patients receiving ghrelin immunisation over 20 weeks, with both active and control groups losing 3.6 kg weight [92]
Andersen, B